Shanghai Xuerong BiotechnologyLtd Beheer

Beheer criteriumcontroles 2/4

De CEO Shanghai Xuerong BiotechnologyLtd is Yongping Yang, benoemd in Apr2022, heeft een ambtstermijn van 2.58 jaar. bezit rechtstreeks 21.57% van de aandelen van het bedrijf, ter waarde CN¥ 412.13M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.6 jaar en 1.9 jaar.

Belangrijke informatie

Yongping Yang

Algemeen directeur

CN¥1.0m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	2.6yrs
Eigendom CEO	21.6%
Management gemiddelde ambtstermijn	2.6yrs
Gemiddelde ambtstermijn bestuur	1.9yrs

Recente managementupdates

Recent updates

CEO

Yongping Yang (55 yo)

2.6yrs

Tenure

CN¥1,026,600

Compensatie

Mr. Yongping Yang serves as Chairman of Shanghai Xuerong Bio-Technology Co., Ltd. and serves as its General Manager since April 12, 2022. Mr. Yang serves as Honorary President of Fujian Chamber of Commerce...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Yongping Yang	Chairman & GM	2.6yrs	CN¥1.03m	21.57% CN¥ 412.1m
Yong Lu	Deputy GM & Non-Independent Director	no data	CN¥845.30k	geen gegevens
Wei Guo	Deputy GM & Non-Independent Director	2.6yrs	CN¥1.01m	0.012% CN¥ 229.8k
Yongkang Gu	Board Secretary	5.9yrs	CN¥717.00k	0.0059% CN¥ 112.0k

2.6yrs

Gemiddelde duur

48.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 300511 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Yongping Yang	Chairman & GM	no data	CN¥1.03m	21.57% CN¥ 412.1m
Yong Lu	Deputy GM & Non-Independent Director	2.5yrs	CN¥845.30k	geen gegevens
Wei Guo	Deputy GM & Non-Independent Director	1.9yrs	CN¥1.01m	0.012% CN¥ 229.8k
Lihua Mao	Non-Employee Supervisor	7.3yrs	geen gegevens	geen gegevens
Jianchun Huang	Independent Director	4yrs	CN¥120.00k	geen gegevens
Jie Li	Director	1.7yrs	CN¥773.50k	0.0096% CN¥ 183.8k
Xueyao Li	Independent Director	1.5yrs	CN¥120.00k	geen gegevens
Danmeng Li	Independent Director	1.3yrs	CN¥42.60k	geen gegevens

1.9yrs

Gemiddelde duur

49.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 300511 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.9 jaar), wat duidt op een nieuw bestuur.

Shanghai Xuerong BiotechnologyLtd Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

High number of new directors

Shanghai Xuerong Biotechnology Co.,Ltd., Annual General Meeting, May 17, 2024

Shanghai Xuerong Biotechnology Co.,Ltd. Approves Board Appointments

Less than half of directors are independent

Less than half of directors are independent

Shanghai Xuerong Biotechnology Co.,Ltd. Approves By-Election of Directors

Recent updates

Third quarter 2024 earnings released: CN¥0.041 loss per share (vs CN¥0.38 loss in 3Q 2023)

Shanghai Xuerong Biotechnology Co.,Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Second quarter 2024 earnings released: CN¥0.32 loss per share (vs CN¥0.34 loss in 2Q 2023)

Shanghai Xuerong Biotechnology Co.,Ltd. (SZSE:300511) agreed to acquire remaining 31.03% stake in Lintao Xuerong Biotechnology Co., Ltd. from Gansu Green and Ecological Industry Development Government Guided Fund Management Co., Ltd. for approximately CNY 45 million.

High number of new directors

Shanghai Xuerong Biotechnology Co.,Ltd. to Report First Half, 2024 Results on Aug 29, 2024

New minor risk - Share price stability

Shanghai Xuerong Biotechnology Co.,Ltd., Annual General Meeting, May 17, 2024

First quarter 2024 earnings released: EPS: CN¥0.01 (vs CN¥0.45 in 1Q 2023)

Shanghai Xuerong Biotechnology Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Shanghai Xuerong Biotechnology Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

New major risk - Financial position

Third quarter 2023 earnings released: CN¥0.38 loss per share (vs CN¥0.12 profit in 3Q 2022)

Shanghai Xuerong Biotechnology Co.,Ltd. to Report Q3, 2023 Results on Oct 30, 2023

Second quarter 2023 earnings released: CN¥0.34 loss per share (vs CN¥0.30 loss in 2Q 2022)

Shanghai Xuerong Biotechnology Co.,Ltd. Approves Board Appointments

Less than half of directors are independent

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.11 loss in 3Q 2021)

Third quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.11 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.30 loss per share (vs CN¥0.37 loss in 2Q 2021)

Shanghai Xuerong Biotechnology Co.,Ltd. Approves By-Election of Directors

Shanghai Xuerong Biotechnology Co.,Ltd. Announces Final Cash Dividend Proposal for 2021

First quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.24 in 1Q 2021)

Now 21% undervalued

Second quarter 2021 earnings released: CN¥0.37 loss per share (vs CN¥0.033 loss in 2Q 2020)

Shanghai Xuerong Biotechnology Co.,Ltd. Announces to Implement Final Cash Distribution Plan for 2020, Payable on 14 May 2021

Shanghai Xuerong Biotechnology Co., Ltd. Approves Cash Dividend for the Year 2020

First quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.40 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.57 (vs CN¥0.51 in FY 2019)

Investor sentiment improved over the past week

New 90-day low: CN¥10.82

New 90-day low: CN¥12.17

New 90-day low: CN¥13.30

New 90-day low: CN¥13.81

New 90-day low: CN¥14.39

Shanghai Xuerong Biotechnology Co.,Ltd. announced that it expects to receive CNY 2.25 billion in funding

Third quarter earnings released

First half earnings released

New 90-day high - CN¥19.22

Shanghai Xuerong Biotechnology Co.,Ltd. to Report First Half, 2020 Results on Aug 27, 2020

New 90-day high - CN¥18.35

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd